Global dyslipidemia market is expected to rise gradually to an estimated value of USD 27.52 billion by 2026: A Report By AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceu

Dyslipidemia is a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc.
According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.

Global dyslipidemia market is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.

Download Sample PDF Report https://databridgemarketresearch.com/request-a-sample/?dbmr=global-dyslipidemia-market

Key Market Competitors: Global Dyslipidemia Market
Few of the major competitors currently working in the Dyslipidemia market are
• AstraZeneca (UK)
• Merck, Pfizer
• Sanofi
• Alnylam Pharmaceuticals
• Amarin Corporation
• Amgen
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis
• Cipla Inc.
• CJ HealthCare
• CKD Bio
• Daewoong Pharmaceutical
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Lupin Pharmaceuticals and few among others

Key Developments in the Market:
• In the year 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that Praluent (alirocumab) in phase 3 clinical trialdemonstrated the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack.
• In the year 2018, Amgen Inc. announced the launch of Repatha (Evolocumab) in the US for the indication of heart attacks and stroke due to high cholesterol at a reduced price to gain more customers.
• In the year 2015, WuXi PharmaTech announced its partnership with Eli Lilly to develop, manufacture, and commercializes in China a Lilly-discovered oral experimental drug for cardiovascular risk in patients with dyslipidemia.

Get Detailed TOC https://databridgemarketresearch.com/toc/?dbmr=global-dyslipidemia-market

Market Drivers
• Increase in global geriatric population
• Increase in prevalence of lifestyle diseases
• Rise in acceptance of telemental health
• Increase in availability of generic drugs
Market Restraints
• Lack of R&D initiatives in this area.
• patent expiry for some blockbuster drugs
• Fewer Government initiatives taken in this direction.

Segmentation: Global Dyslipidemia Market
By Product type
• Statin Drugs
o High-intensity
o Moderate-intensity
o Low-intensity
• Non-Statin Lipid–Lowering Drugs
o Bile Acid Sequestrants
o Cholestyramine
o Colesevelam
o Cholybar
o Colestipol
o Cholesterol Absorption Inhibitor
o Fibrates
o Nicotinic Acid
o PCSK9 Monoclonal Antibodies
o omega-3 Fatty Acids
o Combination Products
By Types
• Primary dyslipidemia
• Secondary dyslipidemia
By Distribution Channel
• Hospitals Pharmacies
• Drug Store
• Online Pharmacies
• Retail Pharmacies
By End- User
• Hospital and Clinics
• Medical laboratories
• Others

Competitive Analysis:
Global dyslipidemia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of dyslipidemia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Speak to Author https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-dyslipidemia-market

Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.